Getting hold of Kedalion's device that delivers topical drugs to the eye with comparable effect but with up to an 80% reduction in dose compared to standard eye drops bodes well for Novartis's ophthalmology business.
Novartis acquires Kedalion Therapeutics and its innovative ocular delivery platform